Gold River Productions (GRPS) announces distribution plans and finalization of R&D for three unique-formulation supplements: Inflammaplex, Painplex and Energyplex

Palm Coast, Florida, June 23, 2021 (GLOBE NEWSWIRE) -- Gold River Productions (OTC Pink: GRPS), through its distribution partner, All Star Health Brands Inc, expects to commence distribution and sales of three of its unique-formulated supplements as well as the first set of products within its long-awaited gummy line. This distribution will expand to certain international markets within the next six months. Ongoing discussions are in place with Jamaican and US distributors. Other markets may include Canada and parts of Latin America.

“We are excited to finally commence the sales and distribution process,” says Richard Goulding, MD, Chairman of the board of GRPS. “This, of course, is just the start. Our supplier was diligently perfecting packaging for delivery of each final product. Now that we have our first packaged products, we can start to ramp up production and purchase orders.”

Gold River is now also working with Eden Labs to ensure the quality of its products. Eden labs is not just any lab, it is the only one that truly understood the unique formulations and respected the quality aspect of the products of Gold River Productions. After months of interviewing several production facilities, Eden emerged as the only one that Gold River Productions truly felt could make these concepts come to life in a satisfactory manner.

Gold River can now commence marketing of its three long-awaited nutraceutical formulations, in addition to the gummy products. Dr. Goulding explains “The beauty of these products is the immediacy of response. The Energyplex formulation is truly amazing. I’ve tried this with an early formulation and the energy boost without sugar and caffeine was substantial. However, the taste of the herbs was unpleasant. In capsule form we’ve eliminated the negative taste.” Painplex works in conjunction with the Raspberry Relief Gummy, and the Inflammaplex is a powerful formula designed for daily use.

*Note: These products have not been evaluated by the FDA. We make no claims that these or any of our products are cures or treatments for any disease.

ESC, a public charity, has provided funding to Gold River, given the public benefit factors of its activities. We welcome any donations to our associated charity: Epidemiologic Solutions Corporation (ESC), which can be done by visiting this website:

Contributions are tax-deductible in accordance with the provisions of Internal Revenue Code Sections 26 U.S. Code §170 and §501©(3). We also welcome suggestions.

DISCLAIMER: Epidemiologic Solutions Corporation seeks donations. Payments to ESC do not constitute an investment; there is no quid pro quo. By making a donation, one does not receive any kind of equity or non equity benefit that specifically accrues to the donor. Instead, we only hope that you and others will help to make the world a better place.

CONTACT:

Epidemiologic Solutions Corporation





Twitter:

About Gold River Productions Inc., GRPS: 

Gold River will focus on market-targeted products including, but not limited to rare cannabinoids and effective products where a particular need is identified.  Products for pain relief, sleep, etc. that will be distributed through convenience stores, independent pharmacies and some proprietary products through physicians.

CONTACT: 

Gold River Productions, Inc.

 



Twitter:

Safe Harbor Notice

Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance.  Forward-looking statements are based on estimates and opinions of management at the time statements are made.  These statements may address issues that involve significant risks, uncertainties, estimates made by management.  Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.